Hypothesis

Osteocalcin’s opposing hepatic and pancreatic actions are balanced by a muscle‑derived myokine that biases GPRC6A signaling toward different G‑protein pathways, and aging‑related bone‑marrow senescence blunts this bias, uncoupling the endocrine axis.

Rationale

Osteocalcin (OCN) stimulates insulin secretion in β‑cells via GPRC6A while simultaneously driving gluconeogenesis in hepatocytes. It's paradoxical that exogenous OCN raises insulin without causing hypoglycemia, implying a built‑in counter‑regulation. Recent work shows that during exercise OCN triggers IL‑6 release from muscle, which feeds back to bone to increase osteoclast activity and OCN release [2]. It's known that IL‑6 acts as a biased ligand for several GPCRs, stabilizing distinct receptor conformations that favor Gαs or Gαq coupling [4]. We're proposing that IL‑6, released in proportion to muscle contraction intensity, binds to GPRC6A in a tissue‑specific manner: in pancreatic β‑cells it promotes a Gαs‑biased state that enhances cAMP‑mediated insulin exocytosis, whereas in hepatocytes it favors a Gαq‑biased state that raises intracellular Ca²⁺ and activates PEPCK‑driven gluconeogenesis. This bias explains how a single hormone can activate opposing metabolic routes without net hypoglycemia.

A second layer involves the carboxylation controversy. It's observed that total OCN correlates better with metabolic health in humans than undercarboxylated OCN [1]. We suggest that total OCN reflects the pool of newly secreted hormone that has not yet undergone tissue‑specific biasing; only the fraction that encounters IL‑6‑primed GPRC6A becomes functionally active. Thus, total OCN serves as a reservoir whose functional fraction is regulated by IL‑6 levels.

Aging introduces senescent cells in the bone marrow microenvironment that secrete SASP factors, including TGF‑β and PAI‑1, which suppress muscle‑derived IL‑6 signaling and osteoblast activity [4]. It's been shown that reduced IL‑6 availability diminishes the biasing effect on GPRC6A, leading to a loss of tissue‑specific signaling fidelity. Consequently, OCN can't act uniformly across tissues without losing its balancing act, disrupting the hepatic‑pancreatic balance and contributing to age‑related glucose intolerance.

Testable Predictions

1. Biased signaling: In isolated mouse islets, adding recombinant IL‑6 will increase OCN‑stimulated cAMP production and insulin release; in primary hepatocytes, the same IL‑6 pretreatment will amplify OCN‑induced IP₃/Ca²⁺ signaling and PEPCK expression.
2. Exercise dose‑response: Mice subjected to graded treadmill intensities will show a correlative rise in circulating IL‑6, OCN‑GPRC6A Gαs bias in pancreas (measured by BRET‑based Gαs activation), and Gαq bias in liver.
3. Aging disruption: Aged (24‑month) mice will exhibit lower muscle IL‑6 after acute exercise, reduced GPRC6A bias in target tissues, and a blunted OCN‑mediated increase in both insulin and gluconeogenic genes compared with young controls.
4. Senescence rescue: Pharmacological clearance of bone‑marrow senescent cells (e.g., navitoclax) in aged mice will restore exercise‑induced IL‑6 levels, re‑establish biased GPRC6A signaling, and normalize glucose tolerance during OCN challenge.

Experimental Approach

• Use BRET biosensors for Gαs and Gαq activation in MIN6 β‑cells and AML12 hepatocytes, treating with OCN ± IL‑6.
• Measure downstream readouts: cAMP ELISA, insulin secretion (ELISA), IP₃ accumulation, glucose output, PEPCK mRNA (qPCR).
• In vivo: young vs. aged mice, treadmill protocols, serial blood sampling for IL‑6, total and undercarboxylated OCN, insulin, glucose.
• Tissue‑specific GPRC6A knockdown (Cre‑lox) to confirm bias originates from receptor, not downstream effectors.
• Senescence models: irradiation or genetic p16‑INK⁺⁺‑driven clearance; assess SASP cytokines in bone marrow flushes.
• Glucose tolerance tests with OCN injection to evaluate net hormonal effect.

Potential Outcomes & Interpretation

If IL‑6 biases GPRC6A as predicted, we will see opposite G‑protein activation patterns that match tissue‑specific metabolic outputs. Loss of this bias in aged or senescent‑clearance‑deficient mice will cause OCN to produce either excess insulin (risk of hypoglycemia) or excessive gluconeogenesis (hyperglycemia), breaking the homeostatic balance. A rescue of bias by senolysis would directly link bone‑marrow aging to systemic metabolic dysfunction via the OCN axis, providing a mechanistic bridge between osteocyte senescence, impaired bone turnover, and age‑related glucose intolerance.